All Stories

  1. Two-year persistence of MERS-CoV-specific antibody and T cell responses after MVA-MERS-S vaccination in healthy adults
  2. Assessment of SARS-CoV-2 immune escape using antigenic cartography combined with experimental challenge studies
  3. Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccination
  4. Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccination
  5. SARS-CoV-2 cross-reactive B-cells outnumber seasonal coronavirus spike-specific clones at the end of the COVID-19 pandemic
  6. Human organoid models to study coronavirus infections of the respiratory tract
  7. Assessment of SARS-CoV-2 immune escape using antigenic cartography combined with experimental challenge studies
  8. The role of gowns in preventing nosocomial transmission of respiratory viruses: a systematic review
  9. Long-term culture of chicken tracheal organoids for the purpose of avian influenza virus research
  10. Variable DPP4 expression in multiciliated cells of the human nasal epithelium as a determinant for MERS-CoV tropism
  11. A pan-orthohantavirus human lung xenograft mouse model and its utility for preclinical studies
  12. A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories
  13. Characterization of a SARS-CoV-2 Omicron BA.5 direct-contact transmission model in hamsters
  14. Detection of Double-Stranded RNA Intermediates During SARS-CoV-2 Infections of Syrian Golden Hamsters with Monoclonal Antibodies and Its Implications for Histopathological Evaluation of In Vivo Studies
  15. Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial
  16. Resistance to SARS-CoV-2 infection in camelid nasal organoids is associated with lack of ACE2 expression
  17. Advancing COVID-19 diagnostics: rapid detection of intact SARS-CoV-2 using viability RT-PCR assay
  18. Characterization of a SARS-CoV-2 Omicron BA.5 direct-contact transmission model in hamsters
  19. Dissecting humoral immune responses to an MVA-vectored MERS vaccine in humans using a systems serology approach
  20. Virus neutralization assays for human respiratory syncytial virus using airway organoids
  21. Profiling the SARS-CoV-2-specific T-cell response
  22. Nachweis doppelsträngiger RNS-Intermediate bei verschiedenen Varianten des schweren akuten respiratorischen Syndrom-Coronavirus-2 (SARS-CoV-2) in formalinfixiertem, paraffineingebettetem Lungengewebe experimentell infizierter Hamster
  23. Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera
  24. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters
  25. Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
  26. An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution
  27. Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models
  28. A pan-orthohantavirus preclinical human lung xenograft mouse model
  29. Presence of procoagulant peripheral blood mononuclear cells in severe COVID-19 patients relate to ventilation perfusion mismatch and precede pulmonary embolism
  30. Human metapneumovirus infection of organoid-derived human bronchial epithelium represents cell tropism and cytopathology as observed in in vivo models
  31. Identification of a Spike-Specific CD8+ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in Humans
  32. Human conjunctiva organoids to study ocular surface homeostasis and disease
  33. The Safety, Immunogenicity, and Optimal Dosing of an MVA-Based Vaccine Against MERS Coronavirus in Healthy Adults: A Phase 1b, Randomised, Placebo-Controlled, Double-Blind Clinical Trial
  34. Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera
  35. Transient Autoreactive PF4 and Antiphospholipid Antibodies in COVID-19 Vaccine Recipients
  36. Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry
  37. Comparative Pathogenesis of Severe Acute Respiratory Syndrome Coronaviruses
  38. Antigenic evolution of SARS coronavirus 2
  39. The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses
  40. Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera
  41. SARS-CoV-2 ORF8 accessory protein is a virulence factor
  42. Distinct COVID-19 vaccine combinations result in divergent immune responses
  43. Glycosylated extracellular mucin domains protect against SARS-CoV-2 infection at the respiratory surface
  44. SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models
  45. Filamentous Fungus-Produced Human Monoclonal Antibody Provides SARS-CoV-2 Protection in Hamster and Non-Human Primate Models
  46. Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD-based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica C1
  47. Correction for Mols et al., “Intestinal Tropism of a Betacoronavirus ( Merbecovirus ) in Nathusius’s Pipistrelle Bat (Pipistrellus nathusii), Its Natural Host”
  48. Detection of double-stranded RNA intermediates of four major SARS-CoV-2 variants in formalin-fixed paraffin-embedded lung tissue of Syrian golden hamsters using monoclonal antibodies
  49. SARS-CoV-2 (B1.1.529) Omicron variant: what has changed in the nose?
  50. ICTV Virus Taxonomy Profile: Coronaviridae 2023
  51. The pro-inflammatory response to influenza A virus infection is fueled by endothelial cells
  52. Mpox Virus Impact on Kidney Organoids and Antiviral Treatment Response
  53. Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica, C1.
  54. Extended Viral Shedding of MERS-CoV Clade B Virus in Llamas Compared with African Clade C Strain
  55. Intestinal Tropism of a Betacoronavirus ( Merbecovirus ) in Nathusius’s Pipistrelle Bat ( Pipistrellus nathusii ), Its Natural Host
  56. Brief Report: Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Subjects Vaccinated with Modified Vaccinia Virus Ankara Encoding MERS-Coronavirus Spike Protein
  57. Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants
  58. Reduced Seasonal Coronavirus Antibody Responses in Children Following COVID-19 Mitigation Measures, The Netherlands
  59. Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1
  60. Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals
  61. Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals
  62. The pro-inflammatory response to influenza A virus infection is fueled by endothelial cells
  63. Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial
  64. Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
  65. Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
  66. Recapitulating infection, thermal sensitivity and antiviral treatment of seasonal coronaviruses in human airway organoids
  67. Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
  68. Protective efficacy of an RBD-based Middle East respiratory syndrome coronavirus (MERS-CoV) particle vaccine in llamas
  69. Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct
  70. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters
  71. Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern
  72. An early warning system for emerging SARS-CoV-2 variants
  73. Review 1: "Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets"
  74. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
  75. Methods for fighting emerging pathogens
  76. Defining the risk of SARS-CoV-2 variants on immune protection
  77. SARS-CoV-2 pathogenesis
  78. Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
  79. The glycosylated extracellular domain of MUC1 protects against SARS-CoV-2 infection at the respiratory surface
  80. Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns
  81. Spreading of SARS-CoV-2 from hamsters to humans
  82. Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants
  83. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants
  84. Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
  85. Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets
  86. Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients
  87. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of Syrian golden hamsters (Mesocricetus auratus)
  88. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
  89. SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium
  90. Middle East respiratory syndrome coronavirus infection in camelids
  91. Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients
  92. Experimental and field investigations of exposure, replication and transmission of SARS-CoV-2 in pigs in the Netherlands
  93. Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19
  94. Targeted proteomics as a tool to detect SARS-CoV-2 proteins in clinical specimens
  95. Zoonoses Anticipation and Preparedness Initiative, stakeholders conference, February 4 & 5, 2021
  96. The glycosylated extracellular domain of MUC1 protects against SARS-CoV-2 infection at the respiratory surface
  97. Author Correction: The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology
  98. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses
  99. The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology
  100. Seasonal coronavirus-specific B-cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19 patients
  101. The Post-Acute Phase of SARS-CoV-2 Infection in Two Macaque Species Is Associated with Signs of Ongoing Virus Replication and Pathology in Pulmonary and Extrapulmonary Tissues
  102. Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers
  103. Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test
  104. Interferon-α Auto-Antibodies in Convalescent Plasma Therapy for COVID-19
  105. Science, not speculation, is essential to determine how SARS-CoV-2 reached humans
  106. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
  107. Animal models of SARS-CoV-2 transmission
  108. Advancing lung organoids for COVID-19 research
  109. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
  110. SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model
  111. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
  112. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses
  113. Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures
  114. Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test
  115. The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses
  116. Human organoid systems reveal in vitro correlates of fitness for SARS-CoV-2 B.1.1.7
  117. High Levels of Neutrophil Extracellular Traps Persist in the Lower Respiratory Tract of Critically Ill Patients With Coronavirus Disease 2019
  118. Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation
  119. Author response: Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation
  120. A Single Subcutaneous or Intranasal Immunization with Adenovirus‐Based SARS‐CoV‐2 Vaccine Induces Robust Humoral and Cellular Immune Responses in Mice
  121. 3D visualization of SARS-CoV-2 infection and receptor distribution in Syrian hamster lung lobes display distinct spatial arrangements
  122. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
  123. Review for "A Single Subcutaneous or Intranasal Immunization with Adenovirus‐Based SARS‐CoV‐2 Vaccine Induces Robust Humoral and Cellular Immune Responses in Mice"
  124. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets
  125. Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins
  126. Neutrophil extracellular traps persist at high levels in the lower respiratory tract of critically ill COVID-19 patients
  127. Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation
  128. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)
  129. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination
  130. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
  131. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
  132. Extended Shedding and Enhanced Fitness of the SARS-CoV-2 Variant of Concern B.1.1.7 in Human Organoid Systems
  133. The BNT162b2 mRNA Vaccine Against SARS-CoV-2 Reprograms Both Adaptive and Innate Immune Responses
  134. Susceptibility of rabbits to SARS-CoV-2
  135. Author response: SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
  136. Decision letter: SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
  137. An Organoid‐derived Bronchioalveolar Model for SARS‐CoV‐2 Infection of Human Alveolar‐type II‐like Cells
  138. Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens
  139. Effects of Potent Neutralizing Antibodies from Convalescent Plasma in Patients Hospitalized for Severe SARS-CoV-2 Infection.
  140. The Importance of Biobanking for Response to Pandemics Caused by Emerging Viruses: The European Virus Archive As an Observatory of the Global Response to the Zika Virus and COVID-19 Crisis
  141. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
  142. Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets
  143. Comparison of SARS-CoV-2 infection in two non-human primate species: rhesus and cynomolgus macaques
  144. How the COVID-19 pandemic highlights the necessity of animal research
  145. Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein
  146. Severe COVID-19 patients display a back boost of seasonal coronavirus-specific antibodies
  147. Animal models for COVID-19
  148. The SARS-CoV-2 multibasic cleavage site facilitates early serine protease-mediated entry into organoid-derived human airway cells
  149. Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins
  150. Susceptibility of rabbits to SARS-CoV-2
  151. Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands
  152. SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model
  153. How the COVID-19 pandemic highlights the necessity of animal research
  154. Assessing the extent of SARS-CoV-2 circulation through serological studies
  155. SARS-CoV-2 is transmitted via contact and via the air between ferrets
  156. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
  157. Convalescent Plasma for COVID-19. A randomized clinical trial
  158. Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease 2019 Patients
  159. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome
  160. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
  161. Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants
  162. Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection
  163. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
  164. A human monoclonal antibody blocking SARS-CoV-2 infection
  165. Serologic Detection of Middle East Respiratory Syndrome Coronavirus Functional Antibodies
  166. SARS-CoV-2 productively infects human gut enterocytes
  167. Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment.
  168. SARS-CoV-2 Productively Infects Human Gut Enterocytes
  169. Targeted Proteomics for the Detection of SARS-CoV-2 Proteins
  170. Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome
  171. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model
  172. SARS-CoV-2 is transmitted via contact and via the air between ferrets.
  173. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Seropositive Camel Handlers in Kenya
  174. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development
  175. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
  176. SARS-CoV-2 specific antibody responses in COVID-19 patients
  177. Comparative Pathogenesis Of COVID-19, MERS And SARS In A Non-Human Primate Model
  178. A human monoclonal antibody blocking SARS-CoV-2 infection
  179. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
  180. Authors’ response: Plenty of coronaviruses but no SARS-CoV-2
  181. Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020
  182. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group
  183. Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19
  184. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
  185. Note from the editors: novel coronavirus (2019-nCoV)
  186. Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV
  187. Two-Component Spike Nanoparticle Vaccine Protects Macaques from SARS-CoV-2 Infection
  188. MERS-CoV in Camels but Not Camel Handlers, Sudan, 2015 and 2017
  189. Machine-learning based patient classification using Hepatitis B virus full-length genome quasispecies from Asian and European cohorts
  190. Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections
  191. Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus
  192. ADAR1: “Editor-in-Chief” of Cytoplasmic Innate Immunity
  193. Failure to detect MERS‐CoV RNA in urine of naturally infected dromedary camels
  194. Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors
  195. Lack of Middle East Respiratory Syndrome Coronavirus Transmission in Rabbits
  196. Host Determinants of MERS-CoV Transmission and Pathogenesis
  197. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
  198. Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein
  199. Co-localization of Middle East respiratory syndrome coronavirus (MERS-CoV) and dipeptidyl peptidase-4 in the respiratory tract and lymphoid tissues of pigs and llamas
  200. Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection
  201. Experimental infection of dromedaries with Middle East respiratory syndrome-Coronavirus is accompanied by massive ciliary loss and depletion of the cell surface receptor dipeptidyl peptidase 4
  202. Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels
  203. Multi-hospital outbreak of a Middle East respiratory syndrome coronavirus deletion variant, Jordan: A molecular, serologic, and epidemiologic investigation
  204. Tissue Distribution of the Mers-Coronavirus Receptor in Bats
  205. Cell Tropism of Middle East Respiratory Syndrome Coronavirus in Experimentally Infected Dromedaries
  206. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein
  207. DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients
  208. Phenotypic Differences between Asian and African Lineage Zika Viruses in Human Neural Progenitor Cells
  209. Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients
  210. Middle East respiratory syndrome coronavirus experimental transmission using a pig model
  211. MERS-coronavirus: From discovery to intervention
  212. Genetic diversity of hepatitis C virus in Ethiopia
  213. Tissue Distribution of the MERS-Coronavirus Receptor in Bats
  214. Virus genomes reveal factors that spread and sustained the Ebola epidemic
  215. Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Infection in Camel Workers in Qatar During 2013–2014: A Case-Control Study
  216. Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches
  217. Seroepidemiology of hepatitis B and C virus infections among blood donors in Ethiopia
  218. Livestock Susceptibility to Infection with Middle East Respiratory Syndrome Coronavirus
  219. Respiratory Infection Routes of MERS-CoV in Rabbits
  220. Development of Different Animal Models for Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) Infection
  221. The sample of choice for detecting Middle East respiratory syndrome coronavirus in asymptomatic dromedary camels using real-time reversetranscription polymerase chain reaction
  222. A novel hepatitis B virus subgenotype D10 circulating in Ethiopia
  223. Miscarriage Associated with Zika Virus Infection
  224. Virus genomes reveal the factors that spread and sustained the West African Ebola epidemic.
  225. Naturally occurring recombination in ferret coronaviruses revealed by complete genome characterization
  226. Toward Developing a Preventive MERS-CoV Vaccine—Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14–15, 2015
  227. MERS-CoV Infection of Alpaca in a Region Where MERS-CoV is Endemic
  228. Deletion Variants of Middle East Respiratory Syndrome Coronavirus from Humans, Jordan, 2015
  229. A poxvirus-based vaccine reduces virus excretion after MERS coronavirus infection in dromedary camels
  230. Hepatitis E Virus (HEV) Genotype 3 Infection of Human Liver Chimeric Mice as a Model for Chronic HEV Infection
  231. Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels
  232. Cross host transmission in the emergence of MERS coronavirus
  233. Mers Coronavirus Infection in Dromedary Camels
  234. Ebola virus laboratory response: the three Dutch Mobile laboratories in Liberia and Sierra Leone
  235. Molecular epidemiology and genetic diversity of hepatitis B virus in Ethiopia
  236. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
  237. Intrathecal CD4+and CD8+T-cell responses to endogenously synthesized candidate disease-associated human autoantigens in multiple sclerosis patients
  238. Genotypic anomaly in Ebola virus strains circulating in Magazine Wharf area, Freetown, Sierra Leone, 2015
  239. Deployment of Dutch mobile laboratories in the West African Ebola virus response
  240. Follow-up of Contacts of Middle East Respiratory Syndrome Coronavirus–Infected Returning Travelers, the Netherlands, 2014
  241. Novel in vivo and in vitro models of Hepatitis E virus genotype 3 infectivity for chronic human HEV infection
  242. Occupational Exposure to Dromedaries and Risk for MERS-CoV Infection, Qatar, 2013–2014
  243. Detection of Circovirus in Foxes with Meningoencephalitis, United Kingdom, 2009–2013
  244. Asymptomatic Middle East Respiratory Syndrome Coronavirus Infection in Rabbits
  245. Reliable typing of MERS-CoV variants with a small genome fragment
  246. Inflammatory Monocytes Recruited to the Liver within 24 Hours after Virus-Induced Inflammation Resemble Kupffer Cells but Are Functionally Distinct
  247. ATP1A1-Mediated Src Signaling Inhibits Coronavirus Entry into Host Cells
  248. Genome Sequence of Enterovirus D68 and Clinical Disease, Thailand
  249. Identification of Protein Receptors for Coronaviruses by Mass Spectrometry
  250. Mers coronavirus infection of rabbits
  251. High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014
  252. Pathogenesis of Middle East respiratory syndrome coronavirus
  253. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen
  254. Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent Manner
  255. Travel-related MERS-CoV cases: an assessment of exposures and risk factors in a group of Dutch travellers returning from the Kingdom of Saudi Arabia, May 2014
  256. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice
  257. Metagenomic Survey for Viruses in Western Arctic Caribou, Alaska, through Iterative Assembly of Taxonomic Units
  258. Exploring the Potential of Next-Generation Sequencing in Detection of Respiratory Viruses
  259. Geographic Distribution of MERS Coronavirus among Dromedary Camels, Africa
  260. Isolation of MERS Coronavirus from a Dromedary Camel, Qatar, 2014
  261. Novel divergent nidovirus in a python with pneumonia
  262. Geographic Distribution of MERS Coronavirus among Dromedary Camels, Africa
  263. New Viruses in Idiopathic Human Diarrhea Cases, the Netherlands
  264. The Pathology and Pathogenesis of Experimental Severe Acute Respiratory Syndrome and Influenza in Animal Models
  265. Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014
  266. Membrane ectopeptidases targeted by human coronaviruses
  267. Middle East respiratory syndrome coronavirus (MERS-CoV) infections in two returning travellers in the Netherlands, May 2014
  268. Neutralizing the MERS Coronavirus Threat
  269. MERS: emergence of a novel human coronavirus
  270. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
  271. Faculty Opinions recommendation of Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation.
  272. The Novel Human Coronavirus EMC Causes Disease in Macaques but not in Ferrets
  273. Updated Phylogenetic Analysis of Arenaviruses Detected in Boid Snakes
  274. Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013
  275. Adenosine Deaminase Acts as a Natural Antagonist for Dipeptidyl Peptidase 4-Mediated Entry of the Middle East Respiratory Syndrome Coronavirus
  276. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients
  277. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study
  278. Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody
  279. Novel Cyclovirus in Human Cerebrospinal Fluid, Malawi, 2010–2011
  280. Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies
  281. Metagenomic Analysis of the Ferret Fecal Viral Flora
  282. Spiking the MERS-coronavirus receptor
  283. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells
  284. Identification and Characterization of Two Novel Viruses in Ocular Infections in Reindeer
  285. The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Does Not Replicate in Syrian Hamsters
  286. The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies
  287. T-Cell Tropism of Simian Varicella Virus during Primary Infection
  288. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-  treatment
  289. Identification of Multiple Novel Viruses, Including a Parvovirus and a Hepevirus, in Feces of Red Foxes
  290. Specific serology for emerging human coronaviruses by protein microarray
  291. Detection of novel divergent arenaviruses in boid snakes with inclusion body disease in The Netherlands
  292. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
  293. Modeling Host Genetic Regulation of Influenza Pathogenesis in the Collaborative Cross
  294. Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection
  295. Presence of anti-interferon antibodies is not associated with non-response to peginterferon treatment in chronic hepatitis B
  296. State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans
  297. Human Coronavirus EMC Does Not Require the SARS-Coronavirus Receptor and Maintains Broad Replicative Capability in Mammalian Cell Lines
  298. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections
  299. Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans
  300. Performance Evaluation of the New Roche cobas AmpliPrep/cobas TaqMan HCV Test, Version 2.0, for Detection and Quantification of Hepatitis C Virus RNA
  301. Picobirnaviruses in the Human Respiratory Tract
  302. Novel Hepatitis E Virus in Ferrets, the Netherlands
  303. Calicivirus from Novel Recovirus Genogroup in Human Diarrhea, Bangladesh
  304. Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3
  305. Expression Quantitative Trait Loci for Extreme Host Response to Influenza A in Pre-Collaborative Cross Mice
  306. Metagenomic Analysis of the Viral Flora of Pine Marten and European Badger Feces
  307. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C
  308. Contents
  309. Enteric Coronavirus in Ferrets, the Netherlands
  310. Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy
  311. A Recombinant Influenza A Virus Expressing Domain III of West Nile Virus Induces Protective Immune Responses against Influenza and West Nile Virus
  312. Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms
  313. Distinct Severe Acute Respiratory Syndrome Coronavirus-Induced Acute Lung Injury Pathways in Two Different Nonhuman Primate Species
  314. Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients
  315. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon–ribavirin combination therapy after 4 weeks of treatment
  316. Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: Implications for treatment outcomes
  317. 2011 IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-α AND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION
  318. Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations?
  319. Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates
  320. Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics
  321. The Application of Genomics to Emerging Zoonotic Viral Diseases
  322. Detection and biological activity of therapeutically induced antibodies to peg-IFN-α-2a in hepatitis C virus infected patients
  323. Interferon response in murine plasmacytoid dendritic cells after SARS coronavirus infection
  324. Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection
  325. Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection
  326. SARS
  327. Unraveling the complexities of the interferon response during SARS-CoV infection
  328. Virogenomics: the virus–host interaction revisited
  329. 27 Severe SARS coronavirus infection in aged macaques is associated with reduced expression of anti-inflammatory type-1 interferons
  330. DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN-α and TNF-α
  331. Pathology of Experimental SARS Coronavirus Infection in Cats and Ferrets
  332. Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees
  333. ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B
  334. Complete genome analysis of hepatitis C virus subtypes 6t and 6u
  335. Severe acute respiratory syndrome (SARS) vaccines
  336. Contributors
  337. Modelling of Early Viral Kinetics and Pegylated Interferon-α2b Pharmacokinetics in Patients with HBeAg-Positive Chronic Hepatitis B
  338. HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project)
  339. Induction of Regulatory T-Cells and Interleukin-10-Producing Cells in Non-Responders to Pegylated Interferon-α Therapy for Chronic Hepatitis B
  340. Differential antiviral effect of PEG-interferon-??-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients
  341. Characterization of Hepatitis C Virus Deletion Mutants Circulating in Chronically Infected Patients
  342. [520] PREDICTION OF SUSTAINED ALT NORMALIZATION BY VIRAL LOAD DURING PEG-IFN ALPHA-2b TREATMENT FOR HBeAg-POSITIVE CHRONIC HEPATITIS B
  343. P1889 Pharmacokinetic profiles in chronic hepatitis C patients treated with high-dose pegylated interferon
  344. Functional Genomics Highlights Differential Induction of Antiviral Pathways in the Lungs of SARS-CoV–Infected Macaques
  345. The emerging role of ACE2 in physiology and disease
  346. Mycophenolic Acid Inhibits Hepatitis C Virus Replication and Acts in Synergy With Cyclosporin A and Interferon-α
  347. Interferon (IFN)–γ–Inducible Protein–10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN‐α2a and Ribavirin for Chronic Hepatitis C Virus Infection
  348. Novel in-vitro and in vivo models
  349. Genotyping Hepatitis C Viruses from Southeast Asia by a Novel Line Probe Assay That Simultaneously Detects Core and 5' Untranslated Regions
  350. Interferon-γ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells
  351. Coronaviruses and their therapy
  352. Identification of a Naturally Occurring Recombinant Genotype 2/6 Hepatitis C Virus
  353. Nonhuman Primate Models for SARS
  354. Antibodies Neutralizing Peginterferon Alfa during Retreatment of Hepatitis C
  355. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response
  356. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
  357. Virus Specific Immune Responses after Human Neoadjuvant Adenovirus-mediated Suicide Gene Therapy for Prostate Cancer
  358. Immunisation with virion-loaded plasmacytoid or myeloid dendritic cells induces primary Th-1 immune responses
  359. Monitoring intrahepatic CD8+ T cells by fine-needle aspiration cytology in chronic hepatitis C infection
  360. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
  361. Host-dependent type 1 cytokine responses driven by inactivated viruses may fail to default in the absence of IL-12 or IFN- / 
  362. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
  363. 848 Neoadjuvant prostate cancer gene therapy: Clinical and pre-clinical results
  364. 494 Analysis of peripheral HCV-specific T cell responses associated with rapid viral decline during PEG-interferon-alfa-2A and ribavirin therapy (DITTO-HCV project)
  365. Pretreatment Intrahepatic CD8 + Cell Count Correlates with Virological Response to Antiviral Therapy in Chronic Hepatitis C Virus Infection
  366. SARS virus infection of cats and ferrets
  367. Prostate cancer gene therapy: Preliminary clinical and pre-clinical results
  368. Prostate cancer gene therapy: Preliminary clinical and pre-clinical results
  369. The glycosylation status of the murine hepatitis coronavirus M protein affects the interferogenic capacity of the virus in vitro and its ability to replicate in the liver but not the brain
  370. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C
  371. Comparative study of different methods to genotype hepatitis C virus type 6 variants
  372. Pretreatment intrahepatic CD8+ cell number correlates with virological response to antiviral therapy in chronic hepatitis C
  373. Molecular epidemiology of gibbon hepatitis B virus transmission
  374. Rat testicular germ & sertoli cells release different types of bioactive TGF-β in vitro
  375. Protective Antiviral Immune Responses to Pseudorabies Virus Induced by DNA Vaccination Using Dimethyldioctadecylammonium Bromide as an Adjuvant
  376. DITTO-HCV early viral kinetics report - novel decline patterns in gen 1 but not gen 2–3 patients treated with PEG-interferon-alfa-2a and ribavirin
  377. Long-term HBV kinetics classification during treatment with adefovir dipivoxil
  378. Identification and characterisation of adenovirus specific T cell responses in prostate cancer patients receiving ADV5-RSV-TK gene therapy
  379. Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus
  380. Corrigendum to “A DNA vaccine coding for glycoprotein B of pseudorabies virus induces cell-mediated immunity in pigs and reduces virus excretion early after infection” [Vet. Immunol. Immunopathol. 74 (2000) 121–136]
  381. Foreign-body reaction to dermal sheep collagen in interferon-?-receptor knock-out mice
  382. A DNA vaccine coding for glycoprotein B of pseudorabies virus induces cell-mediated immunity in pigs and reduces virus excretion early after infection
  383. Cytokine mRNAs in liver biopsy samples predict complete virus eradication with interferon-α ribavirin treatment in chronic hepatitis
  384. Vaccination of pigs against pseudorabies virus with plasmid DNA encoding glycoprotein D
  385. Effect of vaccination route and composition of DNA vaccine on the induction of protective immunity against pseudorabies infection in pigs
  386. Mice Lacking IL-12 Develop Polarized Th1 Cells During Viral Infection
  387. Persistence and Evolution of Feline Coronavirus in a Closed Cat-Breeding Colony
  388. Neutrophil induced T-cell apoptosis during a viral infection
  389. Neutrophil induced T-cell apoptosis during a viral infection
  390. Virus-induced type-1 cytokine response in IL-12 deficient mice
  391. Vaccination of pigs with plasmid DNA coding for glycoproteins of pseudorables virus provides protection against challenge infection with pseudorables virus
  392. Transforming growth factor beta production during rat cytomegalovirus infection.
  393. Apoptosis and T-cell depletion during feline infectious peritonitis.
  394. Tumour necrosis factor-  production during cytomegalovirus infection in immunosuppressed rats
  395. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees
  396. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees
  397. Suppression of rat cytomegalovirus replication by antibodies against gamma interferon.
  398. Tumor necrosis factor alpha promotes replication and pathogenicity of rat cytomegalovirus.
  399. Tumor necrosis factor α levels in cats experimentally infected with feline immunodeficiency virus: effects of immunization and feline leukemia virus infection
  400. Pneumococcal conjugate vaccines
  401. Tumour necrosis factor- , interferon-  and interferon-beta exert antiviral activity in nervous tissue cells
  402. Protection of Rats against Pseudorabies Virus Infection by  -Interferon